Janssen Search
Search results
ASCO 2023
Welcome to the Janssen Oncology Virtual Newsroom Peter Lebowitz, M.D., Ph.D. Global Therapeutic Area Head Oncology Janssen Research & Development, LLC Tyrone Brewer U.S. President Oncology Janssen Biotech, Inc. Latest News Janssen Highlights ...
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Erdafitinib for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations
Sep 08, 2023 Belgium Pending approval, erdafitinib, an investigational, once-daily oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, [1] will become the first therapy targeting FGFR alterations [2] in patients with metastatic ...
Suicide: The Public Health Crisis We Need to Discuss
Suicide: The Public Health Crisis We Need to Discuss Tragically, a suicide takes place every 40 seconds, claiming more than 800,000 lives each year globally. 1 In the United States alone, in 2016 nearly 45,000 Americans age 10 or older died by suicide. ...
Late-breaking results show nipocalimab significantly improves Sjögren’s disease activity in a Phase 2 study
Jun 15, 2024 Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary endpoint compared to patients who received placebo Sjögren’s disease is a chronic, debilitating, and prevalent ...
Building a Better Tomorrow for All
Building a Better Tomorrow for All For decades, vaccines have had an unparalleled impact on global public health and remain one of the most effective methods of preventing infectious diseases worldwide. This year, the World Health Organization (WHO) ...
Dual Perspectives on Digital Twins in Interception Science
Dual Perspectives on Digital Twins in Interception Science In the 1800s, there were several ways to photograph a single image. As image capture was refined, people noticed that successive still photos – or data points – stacked one after another at 10 ...
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non–muscle-invasive bladder cancer
May 03, 2024 New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98% achieving a CR within 12 weeks TAR-200 provides durable CRs in patients with Bacillus Calmette-Guérin (BCG) – unresponsive high-risk non – muscle ...
How We Can Predict Colorectal Cancer Development and Treat it Earlier Than Ever
How We Can Predict Colorectal Cancer Development and Treat it Earlier Than Ever Twenty-one years ago, when President Bill Clinton declared March as National Colorectal Cancer Awareness Month, he highlighted the importance of early detection in improving ...
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
Mar 09, 2024 United States JNJ-2113 long-term extension FRONTIER 2 study demonstrated sustained efficacy from Week 16 to Week 52 and safety results consistent with previously reported data (FRONTIER 1 Study) in a late-breaking oral presentation at the ...
How I Found My ‘I Will’ in Cancer Care
How I Found My ‘I Will’ in Cancer Care Craig Tendler, M.D. is Vice President, Late-Stage Development and Global Medical Affairs for Oncology at Janssen Research & Development, LLC. In medical school some years back, I realized that I wanted to become ...